Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Melanoma 70Neoplasms 47Carcinoma, Non-Small-Cell Lung 26Colorectal Neoplasms 20Neoplasm Metastasis 15Multiple Myeloma 14Thyroid Neoplasms 12Glioma 12Pancreatic Neoplasms 11Hematologic Neoplasms 10Thyroid Carcinoma, Anaplastic 9Brain Neoplasms 8Lung Neoplasms 7Triple Negative Breast Neoplasms 5Rectal Neoplasms 5Neurofibromatosis 1 5Lymphoma 5Leukemia, Myeloid, Acute 5Colonic Neoplasms 5Breast Neoplasms 5Astrocytoma 5Thyroid Cancer, Papillary 4Prostatic Neoplasms 4Neurofibroma, Plexiform 4Glioblastoma 4Cholangiocarcinoma 4Biliary Tract Neoplasms 4Uveal Melanoma 3Skin Neoplasms 3Recurrence 3

Interventions

Irinotecan 8Bevacizumab 8Fluorouracil 7Leucovorin 6Oxaliplatin 5Capecitabine 45,10-methylenetetrahydrofolic acid 3Radiotherapy 2Levoleucovorin 2Folfox protocol 2Drug Therapy 2Cetuximab 2Bisacodyl 2Aspirin 2Artesunate 2trametinib 1spartalizumab 1repotrectinib 1pralsetinib 1pembrolizumab 1nazartinib 1napabucasin 1guadecitabine 1encorafenib 1canakinumab 1camrelizumab 1apatinib 1alectinib 1aldesleukin 1XELOX 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Intestinal Neoplasms × trametinib × Clear all
NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔